Overview

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

Status:
Completed
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in combination in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
LG Chem
Treatments:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Naproxen